CRBP vs WHWK
CRBP: Clinical-stage biopharmaceutical company developing next-generation antibody drug conjugates for oncology and a CB1 receptor inverse agonist for obesity. WHWK: Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload technology.
Side-by-side fundamentals
| Metric | CRBP | WHWK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $8.84 | $3.99 | |
| Market cap as of 2026-07-23 | $163M | $216M | |
| PEG as of 2026-07-23 | -0.04 | n/a | |
| Net margin as of 2026-07-23 | -2838.7% | +99.4% | WHWK higher |
| Gross margin as of 2026-07-23 | n/a | +88.7% | |
| Operating margin as of 2026-07-23 | -4309.7% | +87.4% | WHWK higher |
| ROE as of 2026-07-23 | -70.9% | -79.6% | CRBP higher |
| ROA as of 2026-07-23 | -61.8% | -74.0% | CRBP higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -22.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -22.3% | |
| Beta as of 2026-07-23 | 2.63 | 0.81 | |
| 1-year return as of 2026-07-22 close | +4.9% | +113.4% | WHWK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.